Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2014 | (b) 2015 | (c) 2016 | (d) 2017 | (e) 2018 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 14,884,024 | 13,729,474 | 13,952,247 | 11,921,451 | 12,714,798 | 67,201,994 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.... | 0 | |||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | 0 | |||||
| 4 | Total. Add lines 1 through 3 | 14,884,024 | 13,729,474 | 13,952,247 | 11,921,451 | 12,714,798 | 67,201,994 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | 0 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 67,201,994 | |||||
Calendar year
(or fiscal year beginning in) ![]() |
(a) 2014 | (b) 2015 | (c) 2016 | (d) 2017 | (e) 2018 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 14,884,024 | 13,729,474 | 13,952,247 | 11,921,451 | 12,714,798 | 67,201,994 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 334,775 | 372,780 | 287,499 | 296,562 | 308,859 | 1,600,475 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 363,577 | 341,191 | 348,604 | 284,518 | 259,968 | 1,597,858 |
| 11 | Total support. Add lines 7 through 10 | 70,434,417 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2014 | (b) 2015 | (c) 2016 | (d) 2017 | (e) 2018 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2014 | (b) 2015 | (c) 2016 | (d) 2017 | (e) 2018 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 1-1/2% of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by .035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | ||
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
||
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | ||
| 4 Amounts paid to acquire exempt-use assets | ||
| 5 Qualified set-aside amounts (prior IRS approval required) | ||
| 6 Other distributions (describe in Part VI). See instructions | ||
| 7Total annual distributions. Add lines 1 through 6. | ||
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
||
| 9 Distributable amount for 2018 from Section C, line 6 | ||
| 10 Line 8 amount divided by Line 9 amount | ||
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2018 |
(iii) Distributable Amount for 2018 |
|
|---|---|---|---|---|
|
1
Distributable amount for 2018 from Section C, line 6 |
||||
|
2
Underdistributions, if any, for years prior to 2018 (reasonable cause required-- explain in Part VI). See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2018: | ||||
| a From 2013....... | ||||
| b From 2014....... | ||||
| c From 2015....... | ||||
| d From 2016....... | ||||
| e From 2017....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2018 distributable amount | ||||
|
i
Carryover from 2013 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from 3f. | ||||
| 4Distributions for 2018 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2018 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from 4. | ||||
|
5
Remaining underdistributions for years prior to 2018, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2018. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2019. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2014...... | ||||
| b Excess from 2015..... | ||||
| c Excess from 2016..... | ||||
| d Excess from 2017..... | ||||
| e Excess from 2018..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Go to www.irs.gov/Form990 for the latest information.
| Return Reference | Explanation |
|---|---|
| PART III, LINE 1 - ORGANIZATION'S MISSION: | THE NATIONAL FOUNDATION FOR CANCER RESEARCH ("NFCR") IS A LEADING PUBLIC CHARITY DEDICATED TO FUNDING CANCER RESEARCH AND PUBLIC EDUCATION RELATING TO CANCER PREVENTION, EARLIER DIAGNOSIS, BETTER TREATMENTS AND ULTIMATELY, CURES FOR CANCER. NFCR PROMOTES AND FACILITATES COLLABORATION AMONG SCIENTISTS TO ACCELERATE THE PACE OF DISCOVERY FROM BENCH TO BEDSIDE. SINCE 1973, NFCR HAS PROVIDED MORE THAN $380 MILLION IN SUPPORT OF DISCOVERY-ORIENTED CANCER RESEARCH FOCUSED ON UNDERSTANDING HOW AND WHY CELLS BECOME CANCEROUS, AND ON PUBLIC EDUCATION RELATING TO CANCER PREVENTION, DETECTION, AND TREATMENT. NFCR SCIENTISTS ARE DISCOVERING CANCER'S MOLECULAR MYSTERIES AND TRANSLATING THEIR DISCOVERIES INTO THERAPIES THAT HOLD THE HOPE FOR CURING CANCER. NFCR-FUNDED RESEARCHERS ARE MAKING PROGRESS EVERY DAY IN THEIR PURSUIT OF CANCER CURES, AND THIS IS ONLY POSSIBLE WITH THE FINANCIAL SUPPORT OF MILLIONS OF DONORS NATIONWIDE. ONE STEP AT A TIME, WE ARE GETTING CLOSER TO OUR ULTIMATE GOAL-CURING CANCER, ALL TYPES OF CANCER. FOR MORE INFORMATION, PLEASE VISIT WWW.NFCR.ORG. |
| PART III, LINE 4A - CANCER RESEARCH PROGRM ACCOMPLISHMENTS: | HIGHLIGHTS OF RESEARCH ACCOMPLISHMENTS ======================================== With support from our generous donors, NFCR-funded scientists have made numerous remarkable advances in the fight against cancer. Their research encompasses a wide variety of fields, many of which could ultimately lead to a cure for this deadly disease. A FEW OF THE KEY PROGRESSES ACHIEVED BY NFCR SCIENTISTS IN 2018: 20 Cancer biomarkers identification or evaluation of genetic pieces of cancers vulnerabilities that may lead doctors to earlier diagnoses and precision treatments. 8 New drug candidates and potential therapeutics identification of anticancer agents that could lead to new treatment options desperately needed by patients. 19 Cancer-Related genes and proteins discovery and further exploration of key cancer molecules which could provide new targets for drug development. NOTABLE RESEARCH HIGHLIGHTS ============================== Identifying Patients Likely to Respond to Immunotherapy -------------------------------------------------------- Immunotherapy for metastatic melanoma remarkably increases survival for some patients beyond ten years. For others, the response is minimal and ineffective treatment may continue before standard tests confirm the lack of response. Monitoring an early response to immunotherapy is a challenge. Assessing local immune response from invasive serial tumor biopsies from single metastatic sites may not represent other metastatic sites - the tumor burden - in melanoma, a cancer caused by various genes. To address this challenge, Dr. Daniel Habers team will use their previously developed liquid biopsy blood test that captures circulating tumor cells (CTCs) shed from all tumor sites and present in patients blood samples. They have discovered a signature panel of 19 RNA molecules expressed in captured melanoma CTCs that can be 'scored' to measure tumor burden in response to therapy. CTC RNA scoring blood test at 7 weeks of therapy correlated with marked improvement in survival without tumor growth. Early assessment of treatment response can guide application of immunotherapy. Moreover, CTC RNA signatures may also be identified in other cancers. Daniel Haber, M.D., Ph.D. Combination Therapy for Resistant Lung Cancer ---------------------------------------------- The cornerstone of treatment for patients with ALK-positive non-small cell lung cancer (NSCLC) is 'on target' therapies targeting the cancer-promoting ALK proteins. These therapies have dramatically improved the outlook for patients, but, eventually, almost all patients will develop resistance. their tumors will have developed 'off-target' mechanisms of resistance that activate downstream growth signaling pathways bypassing ALK. To develop a treatment for 'off-target' resistance, a panel of resistant cell lines derived from patients screened with an RNA library identified is Shp2 protein. A Shp2 inhibitor combined with on-target ALK inhibitor in patient-derived cell lines inhibited cancer cell growth. After efficacy of the two drugs is established in pre-clinical models, a first-in-man phase 1 clinical trial treating ALK-positive NSCLC patients will determine if the combination therapy can overcome resistance. Combination therapy could become a front-line therapy, and improve the chance of a durable and complete remission bringing patients one step closer to a cure. Alice T. Shaw, M.D., Ph.D. New Approaches to Treating Pancreatic Cancer --------------------------------------------- Pancreatic cancer, the 3rd leading cause of cancer death in the U.S., has a 5-year survival rate of less than 9%. One reason current treatments have limited activity is tumors are surrounded by stroma - dense fibrotic tissue of immune cells, fat cells, stem cells, fibroblasts and other cells. Stroma interacts with cancer cells, contributing to its aggressiveness and drug resistance. Also, pancreatic cancer cells themselves undergo the EMT (Epithelial-Mesenchymal Transition) process that allows the cells to metastasize and resist treatment. NFCR scientists are developing new treatments for pancreatic cancer by targeting the stroma and the EMT process. With biopsy samples from human tumors and lab models, single cell RNA sequencing identifies all RNA expressed in individual cells, revealing the distinct cell types and signaling pathways that characterize each cell population. From these results, therapies better tailored to a patients tumor are being selected to treat pancreatic cancer patients in a pilot clinical trial. EMT inhibitors are first tested in an EMT assay using zebrafish as a model, before testing in pancreatic cancer models. In this era of precision oncology, the best drugs matched to the individuals targets may further improve care of pancreatic cancer patients who have no other options. Daniel Von Hoff, M.D. Making Inroads to Defeat Metastasis ------------------------------------- At least 90% of cancer deaths are due to a tumors spread or metastasis to vital organs in our body. Dr. Danny Welch, with NFCR funds, has previously discovered eight of the 35 known metastasis suppressor genes. In metastasis, many of these genes are under-expressed and produce minimal or non-existent levels of their proteins, allowing cancer to spread. In KISS1 and BRMSI genes, his team has identified domains (small regions) in each protein that are crucial in suppressing metastasis and interacting with potential protein partners. The idea is to develop small molecules that mimic the activity of the domains and can function as a complete protein to suppress metastasis. In other research, Dr. Welch has developed a complex metastasis cancer model wherein small genetic changes (single nucleotide polymorphisms) may better explain racial disparities in tumor development, as well as better predict metastasis and patient survival. A genetic test on a patients blood sample may help doctors plan treatments more carefully. Danny R. Welch, Ph.D. Research Identifies Potential Guidance for Gastric Cancer Treatment ------------------------------------------------------------------- Researchers from Wake Forest Baptist Medical Center and Tianjin Medical University Cancer Institute and Hospital (TMUCIH) have discovered that gastric cancer tissue samples bearing mutation of a specific gene, MUC16, too are associated with higher tumor mutation loads. Also known as tumor mutation burdens, measurement of high genetic mutation rates among cancerous versus healthy tissue has increasingly been shown to correlate with effective response rates to immunotherapy. The knowledge could bode positively for patients with the biomarker present. Tumors with higher tumor mutation loads tend to be more responsive to immunotherapy. The authors stress the implications that this and other proven biomarkers have on the ability of oncologists to design cancer treatments most likely to succeed. Findings from this study, for example, could serve to open immunotherapy options for up to 38% of gastric cancer patients. Wei Zhang, Ph.D. Attacking Metastatic Tumors in the Brain ------------------------------------------ A discovery by NFCR scientists and collaborators could be very important for patients whose cancers have spread to the brain. About 25% of all breast cancers have an excess of Human Epidermal Growth Factor Receptor 2 (known as HER 2positive or HER2+) which spreads more quickly than other types of breast cancer. HER2+ targeted therapies treat HER2+ breast cancer and patients are in remission for years or longer. However, up to 50% of these patients receiving these targeted therapies eventually develop brain metastases, which are inevitably fatal. Research with tumor models and human cancer samples has determined breast-cancer-associated brain lesions overexpress another related factor, HER3, and that inhibiting HER3 could help overcome treatment resistance. Importantly, HER2 targeted therapy combined with inhibitors to HER3 significantly slowed brain metastatic tumor growth and improved survival in tumor models. This discovery could have a substantial impact on the future development of therapeutic strategies and ultimately, patient survival from this deadly disease. Moreover, since HER3 expression is associated with treatment resistance in several types of cancer, this discovery could potentially benefit a much broader group of patients. Rakesh Jain, Ph.D. |
| PART III, LINE 4B - CANCER PREVENTION EDUCATION TO THE PUBLIC: | NFCR provides the public with free publications containing valuable information on the most up-to-date cancer preventive measures, treatment options, and diagnostic tools. Our powerful message mailed to tens of millions of families and reaching tens of thousands of individuals through our social media channels (twitter and facebook) and through our blogs, helps to assure that fewer of todays healthy individuals will get cancer and more of todays cancer patients will become tomorrows cancer survivors. Our public education materials include early cancer detection guide, a Childhood Cancer Chart, cancer prevention kits, recipes for healthy living, electronic and printed newsletters, the latest cancer headlines, and in-depth online cancer information. |
| PART VI, SECTION A, LINE 2 - DIRECTORS/OFFICERS WITH FAMILY RELATIONSHIPS: | FRANKLIN SALISBURY, CEO, AND SUJUAN BA, PRESIDENT/COO, ARE HUSBAND AND WIFE. |
| PART VI, SECTION B, LINE 11B - REVIEW PROCESS OF FORM 990: | THE NATIONAL FOUNDATION FOR CANCER RESEARCH'S PROCESS FOR REVIEWING THE FORM 990. ======================================================================== 1. FORM 990 WILL BE PREPARED AFTER ANNUAL AUDIT IS DONE. 2. THE FIRST DRAFT WILL BE REVIEWED BY THE CHIEF OPERATING OFFICER AND THE CHIEF FINANCIAL OFFICER. 3. AFTER RESOLVING ANY QUESTIONS OR UPDATES, THE REVISED DRAFT WILL BE SENT TO BOARD MEMBERS, PREFERABLY ELECTRONICALLY FOR THEIR REVIEW AND COMMENTS. 4. THE BOARD MEMBER'S COMMENTS, IF ANY, WILL BE INCORPORATED IN THE FINAL RETURN. 5. THE RETURN WILL BE FILED WITH THE IRS PRIOR TO THE DESIGNATED DUE DATE OR EXTENDED DUE DATE. 6. THE STATE VERSION WILL BE PROVIDED TO STATES FOR REGISTRATION RENEWALS AND THE PUBLIC PORTIONS OF THE RETURN WILL BE POSTED ON THE FOUNDATION'S WEBSITE. 7. IN THE OCCASION THAT THERE IS INSUFFIENT TIME PRIOR TO FILING FORM 990 TO SHARE IT WITH THE BOARD, OR THERE IS ABSENSE OF AN OPPORTUNITY FOR ANY MEANINGFUL REVIEW OF FORM 990 BY THE BOARD PRIOR TO THE FILINGS DEALINE, AN ELECTRONIC VERSION OF THE FILED RETURN WILL BE AVAILABLE FOR BOARD MEMEBER'S REVIEW AND COMMENTS AFTER SUBMISSION OF RETURN TO IRS. AN AMENDED RETURN IF NECESSARY, WILL BE FILED. |
| PART VI, SECTION B, LINE 12C - CONFLICT OF INTEREST POLICY COMPLIANCE: | EACH DIRECTOR, PRIOR TO TAKING HIS/HER POSITION ON THE BOARD, AND ALL PRESENT DIRECTORS SHALL SUBMIT IN WRITING TO THE CHAIRMAN OF THE BOARD A LIST OF ALL BUSINESSES OR OTHER ORGANIZATIONS OF WHICH HE/SHE IS AN OFFICER, DIRECTOR, TRUSTEE, MEMBER, OWNER SHAREHOLDER, EMPLOYEE OR AGENT, WITH WHICH THE FOUNDATION HAS, OR MIGHT REASONABLE IN THE FUTURE ENTER INTO, A RELATIONSHIP OR A TRANSACTION IN WHICH THE DIRECTOR WOULD HAVE CONFLICTING INTEREST ANNUALLY. |
| PART VI, SECTION B, LINE 15A/15B - OFFICERS COMPENSATION: | ON AN ANNUAL BASIS, THE BOARD WILL PERFORM A THOROUGH REVIEW TO DETERMINE SUITABLE COMPENSATION. THIS PROCESS INCLUDES ALL OF THE FOLLOWING THREE ELEMENTS. ======================================================================= 1. REVIEW AND APPROVAL BY BOARD OF DIRECTORS: THE COMPENSATION OF EACH OFFICER IS REVIEWED AND APPROVED BY THE BOARD OF DIRECTORS, PROVIDED THAT PERSONS WITH CONFLICTS OF INTEREST WITH RESPECT TO THE COMPENSATION ARRANGEMENT AT ISSUE ARE NOT INVOLVED IN THIS REVIEW AND APPROVAL. EACH OFFICER'S PERFORMANCE IS EVALUATED BASED ON HIS OR HER JOB RESPONSIBILITIES, AND INTERNAL AND EXTERNAL GOALS SET IN THE PREVIOUS YEAR. 2. REVIEW OF "COMPARABLE COMPENSATION" DATA: THE COMPENSATION OF EACH OFFICER IS REVIEWED AND APPROVED USING DATA AS TO COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS. COMPARABLE DATA ARE COMPILED BY THE FOUNDATION'S CHIEF FINANCIAL OFFICER AND/OR BY OUTSIDE COMPENSATION CONSULTANTS. COMPARABILITY DATA CAN INCLUDE COMPENSATION DATA FROM IRS FORM 990'S OF SIMILAR ORGANIZATIONS, PUBLISHED COMPENSATION SURVEYS, STUDIES AND GUIDES, AND OTHER SOURCES DEEMED APPROPRIATE AT THE TIME. 3. DOCUMENTATION AND RECORDKEEEPING: THERE IS CONTEMPORANEOUS DOCUMENTATION AND RECORDKEEPING WITH RESPECT TO THE DELIBERATIONS AND DECISIONS REGARDING THE COMPENSATION AGREEMENT. THE RECORD IS KEPT BY THE SECRETARY OF THE FOUNDATION. |
| PART VI, SECTION C, LINE19-AVAILABILTY OF DOCUMENTS, POLICIES, AND F/S: | THE FOUNDATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. THE FINANCIAL STATEMENTS ARE ALSO AVAILABLE ON THE FOUNDATION'S WEBSITE. |
| PART IX, LINE 26, JOINT COSTS ALLOCATION: | NFCR IS COMMITTED TO EFFICIENCY AND TRANSPARENCY. FOR MORE THAN 40 YEARS, NFCR HAS BEEN COMMUNICATING WITH SUPPORTERS, DONORS, AND PROSPECTIVE DONORS BY EMAIL, POSTAL EMAIL, PHONE AND OTHER MEANS, BOTH TO REQUEST CONTRIBUTIONS AND TO EDUCATE THE PUBLIC, THEREBY UPHOLDING NFCR'S MISSION STATEMENT (TO SUPPORT CANCER RESEARCH AND PUBLIC EDUCATION RELATING TO THE PREVENTION, EARLY DIAGNOSIS, BETTER TREATMENTS AND ULTIMATELY, A CURE FOR CANCER). THESE FREE PUBLICATIONS ARE SENT TO TENS OF MILLIONS OF FAMILIES AND INCLUDE MATERIALS SUCH AS EARLY DETECTION GUIDES, CHILDHOOD CANCER CHARTS, CANCER PREVENTION KITS AND RECIPES FOR HEALTHY LIVING. AS A RESULT, IN ACCORDANCE WITH THE FINANCIAL ACCOUNTING STANDARDS BOARD (FASB) GUIDELINES SOP 98-2 (ASC 958-720), WE ALLOCATE A PORTION OF OUR DIRECT MAIL COST TO PROGRAM SERVICES AND TO FUNDRAISING. |
| Software ID: | |
| Software Version: |